458 related articles for article (PubMed ID: 24832836)
1. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.
Baji P; Péntek M; Czirják L; Szekanecz Z; Nagy G; Gulácsi L; Brodszky V
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S53-64. PubMed ID: 24832836
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
Bae SC; Lee YH
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
Ho Lee Y; Gyu Song G
Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparison of biological treatments in refractory rheumatoid arthritis.
Gallego-Galisteo M; Villa-Rubio A; Alegre-del Rey E; Márquez-Fernández E; Ramos-Báez JJ
J Clin Pharm Ther; 2012 Jun; 37(3):301-7. PubMed ID: 21831256
[TBL] [Abstract][Full Text] [Related]
7. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.
Migliore A; Bizzi E; Petrella L; Bruzzese V; Cassol M; Integlia D
BioDrugs; 2016 Apr; 30(2):105-15. PubMed ID: 26905069
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
[TBL] [Abstract][Full Text] [Related]
9. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe D; Bombardier C
BMJ; 2016 Apr; 353():i1777. PubMed ID: 27102806
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
[TBL] [Abstract][Full Text] [Related]
13. Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
Genovese MC; Sanchez-Burson J; Oh M; Balazs E; Neal J; Everding A; Hala T; Wojciechowski R; Fanjiang G; Cohen S
Arthritis Res Ther; 2020 Mar; 22(1):60. PubMed ID: 32216829
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
15. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
[TBL] [Abstract][Full Text] [Related]
17. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK
Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J
Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]